Roivant Sciences (NASDAQ:ROIV) Stock: Insider Richard Pulik Sells 125,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CFO Richard Pulik sold 125,000 shares of the business’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $41.20, for a total transaction of $5,150,000.00. Following the completion of the sale, the chief financial officer owned 269,681 shares in the company, valued at $11,110,857.20. This represents a 31.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Richard Pulik also recently made the following trade(s):

• On Wednesday, November 11th, Richard Pulik sold 175,000 shares of Roivant Sciences stock. The shares were sold at an average price of $41.85, for a total transaction of $7,323,750.00.

Roivant Sciences Price Performance

ROIV stock traded down $1.86 during trading on Thursday, hitting $39.99. 8,744,046 shares of the company’s stock traded hands, compared to its average volume of 8,291,942. Roivant Sciences Ltd. has a 52 week low of $19.96 and a 52 week high of $42.50. The business has a fifty day simple moving average of $37.20 and a 200 day simple moving average of $32.16.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ROIV. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. Guggenheim boosted their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 24th. Finally, TD Cowen restated a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.64.

Hedge Funds Weigh In On Roivant Sciences

Large investors have recently made changes to their positions in the company. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Roivant Sciences during the 2nd quarter valued at about $2,166,000. Squarepoint Ops LLC bought a new stake in Roivant Sciences in the second quarter worth about $16,830,000. Sumitomo Mitsui DS Asset Management Company Ltd bought a new stake in Roivant Sciences in the third quarter worth about $2,257,000. Arizona State Retirement System lifted its stake in Roivant Sciences by 24.4% in the second quarter. Arizona State Retirement System now owns 128,364 shares of the company’s stock worth $4,543,000 after purchasing an additional 25,199 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Roivant Sciences during the first quarter valued at approximately $3,957,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.